Search

1例双侧多囊肾去顶术的手术配合及护理

FEV6 as A Surrogate for FVC in the Diagnosis for Mild-Moderate Chronic Obstructive Pulmonary Disease

Objective To determine the efficacy of forced expiratory volume in six seconds( FEV6 ) as an alternative for forced vital capacity( FVC) in the diagnosis for mild-moderate chronic obstructive pulmonary disease( COPD) .Methods A total of 402 mild-moderate COPD and 217 non-COPD patients’ spirometric examinations were retrospectively analyzed. The correlation between FEV6 and FVC, FEV1 /FVC and FEV1 /FEV6 was evaluated by the Spearman test. Considering FEV1 /FVC lt;70% as being the ‘golden standard’ for airway obstruction, a ROC curve was used to determine the best cut-off point for the FEV1 /FEV6 ratio in the diagnosis for COPD. Results The Spearman correlation test revealed the FEV1 and FEV6 , FEV1 /FEV6 and FEV1 /FVC ratios were highly correlated ( r = 0. 992, 0. 980, respectively, P = 0. 000) . Using FEV1 /FEV6 lt; 70% as the diagnosis standard, 12. 69% of the 402 patients could not be diagnosed as COPD. The FEV1 /FVC ratio of these patients was very close to 70% . The best cut-off point for the FEV1 /FEV6 ratio in the diagnosis of mild-moderate COPD was 72% while the sensitivity and specificity were 94. 7% and 92. 2% , respectively. Conclusions There is a b correlation between FEV1 /FVC and FEV1 /FEV6 . The FEV6 can be a valid alternative for FVC in the diagnosis for mild-moderate COPD, although it may result in false negative. The best cut-off point for the FEV1 /FEV6 ratio is 72% .

阿德福韦酯对乙型肝炎病毒e抗原阴性慢性乙型肝炎患者T细胞亚群的影响

目的探讨阿德福韦酯对乙型肝炎病毒e抗原（HBeAg）阴性慢性乙型肝炎患者外周血T细胞亚群的影响。 方法对2012年5月-2013年5月56例慢性乙型肝炎患者常规给予护肝治疗，同时给予口服阿德福韦酯10 mg，1次/d，疗程48周。检测服药前及48周后肝功能、乙型肝炎病毒（HBV） DNA及T细胞亚群。 结果经口服阿德福韦酯治疗48周后，患者血清HBV-DNA滴度较治疗前明显下降，肝功能明显改善，CD4+T淋巴细胞百分比（37.3%） 较治疗前（32.8%） 明显升高（P＜0.001），CD4+/CD8+（1.37） 较治疗前（1.11） 升高（P＜0.005）。 结论阿德福韦酯治疗HBeAg阴性慢性乙型肝炎，在抑制HBV的复制、减轻肝脏炎症反应的同时，也可能改善了慢性乙型肝炎患者的细胞免疫功能。